Vivian Pan

TL;DR: The design and initial implementation of the eMERGE‐PGx project is described, including site‐specific project implementation and anticipated products, including genetic variant and phenotype data repositories, novel variant association studies, clinical decision support modules, clinical and process outcomes, approaches to managing incidental findings, and patient and clinician education methods.

TL;DR: There was low concordance in designating SCN5A and KCNH2 variants as pathogenic in individuals recruited for nonantiarrhythmic drug exposure phenotypes, and these findings raise questions about the implications of notifying patients of incidental genetic findings.

TL;DR: The distribution and scope of genetic variation in relevant pharmacogenes are highlighted, identifying challenges associated with implementing clinical sequencing for drug treatment at a broader level, and underscoring the importance for multifaceted research in the execution of precision medicine.

TL;DR: General consensus among participants indicates the importance of increasing the capacity of the GC workforce pipeline and addressing funding issues, examining current accreditation requirements, and reevaluating current education models may be effective strategies to expanding GC program size.

TL;DR: The results of this study help gain a better understanding of the implications of using exome sequencing in a prenatal setting and development of guidelines is also warranted to aid clinical practice and laboratory standards for reporting prenatal results.